Post
Mirum Pharmaceuticals reports positive data from Chenodal trial
US-based biopharmaceutical company Mirum Pharmaceuticals has reported positive findings from the Phase III RESTORE clinical trial of Chenodal (chenodiol) tablets to treat …
Up to 200,000 to be enrolled in UK winter Covid-19 infection study
Up to 200,000 people could take part in the UK's winter Covid-19 infection study (WCIS), to be conducted by the …
Boehringer Ingelheim and CDR-Life to carry out GA drug trial
Boehringer Ingelheim and CDR-Life are set to begin a Phase I clinical trial to analyse the potential of BI 771716 …
Cassava Sciences enrols all patients in Alzheimer’s drug trial
US-based biopharmaceutical company Cassava Sciences has finished enrolling participants in a Phase III clinical trial of an oral drug candidate, simufilam, to …
Acurx Pharmaceuticals concludes Phase IIb trial of CDI therapy
US-based biopharmaceutical company Acurx Pharmaceuticals has completed a Phase IIb clinical trial of its antibiotic candidate ibezapolstat to treat patients with Clostridioides …
DCT Tracker: Are sponsors getting better at conducting DCTs?
The role of decentralised clinical trials (DCTs) in the clinical trial industry has shifted over the past few years. Moreover, …
Moleculin doses first patients in Phase II portion of AML Annamycin combo study
Moleculin Biotech has dosed the first subjects in the Phase II portion of a Phase Ib/II trial evaluating the company’s …
Syndax leukaemia drug hits endpoint goals ahead of planned new drug application
Clinical-stage biopharmaceutical company, Syndax, has announced that it has met one of its goals as part of a Phase I/II …
Pipeline Moves: Advancement prospects plunge for myelodysplastic syndrome drug after trial termination
This week on Pipeline Moves, we kickoff by looking at the terminations of a Phase II trial in myelodysplastic syndrome …
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Novartis has announced positive interim results for iptacopan from the Phase III Applause-IgAN study showing significant proteinuria reduction in patients …
AbbVie’s venetoclax fails Phase III myeloma trial
AbbVie reported negative results from a Phase III CANOVA trial investigating venetoclax in patients with relapsed or refractory multiple myeloma. The …
Phase III results boost datopotomab deruxtecan’s potential in breast cancer
On 22 September, AstraZeneca announced positive interim data for the Phase III TROPION-Breast01 trial evaluating Daiichi Sankyo and AstraZeneca’s datopotomab …
Signal: Philips knew about ventilator defects for years before recall
Multinational electronics and medical device manufacturer Philips knew for over a decade about the defects in its respiratory devices before …
Limited innovation in the late-stage pipeline for insomnia
Insomnia is the most common sleep disorder, characterised by patient-reported difficulty with sleep initiation and/or sleep maintenance. According to the …
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Regeneron Pharmaceuticals has presented Phase II data for linvoseltamab in patients with relapsed/refractory (r/r) multiple myeloma (MM) who have received …